The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Diabetes Dyslipidemia
Open accessAbstract
Diabetes mellitus is associated with a considerably increased risk of premature atherosclerotic cardiovascular disease. Intensive glycemic control has essentially failed to significantly improve cardiovascular outcomes in clinical trials. Dyslipidemia is common in diabetes and there is strong evidence that cholesterol lowering improves cardiovascular outcomes, even in patients with apparently unremarkable lipid profiles. Here, the authors review the pathophysiology and implications of the alterations in lipoproteins observed in both type 1 and type 2 diabetes, the effect of medications commonly used in the management of diabetes on the lipid profile, the evidence for lifestyle and pharmaceutical interventions, and national and international recommendations for the management of dyslipidemia in patients with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Cited by
Lingvay, I., Catarig, A.-M., Frias, J. P., Kumar, H., Lausvig, N. L., le Roux, C. W., Thielke, D., Viljoen, A., & McCrimmon, R. J. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30311-0 · Cited by 298
Vitamin C supplementation for diabetes management: A comprehensive narrative review
Mason, S. A., Parker, L., van der Pligt, P., & Wadley, G. D. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.12.003 · Cited by 53
Marincic, P. Z., Salazar, M. V., Hardin, A., Scott, S., Fan, S. X., Gaillard, P. R., Wyatt, C., Watson, L., Green, P., Glover, P., et al. (2019) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2018.06.303 · Cited by 51
Treatment of dyslipidemia in diabetes: recent advances and remaining questions
Chait, A., & Goldberg, I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0942-8 · Cited by 40
Effects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease
Wright, R. S., Ray, K. K., Landmesser, U., Koenig, W., Raal, F. J., Leiter, L. A., Conde, L. G., Han, J., & Schwartz, G. G. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.03.025 · Cited by 25
Metadata
- Authors
- Schofield, J. D., Liu, Y., Rao-Balakrishna, P., Malik, R. A., & Soran, H.
- Venue
- Diabetes Therapy
- Published
- 2016-04-07
- Volume
- 7
- Issue
- 2
- Pages
- 203-219
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- OpenAlex
- W3187443279
- Cited by
- 417
- References
- 136
- FWCI
- 29.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetes Dyslipidemia. https://app.cochat.ai/papers/10.1007/s13300-016-0167-x
- The paper
- Schofield, J. D., Liu, Y., Rao-Balakrishna, P., Malik, R. A., & Soran, H. (2016). Diabetes Dyslipidemia. Diabetes Therapy. https://doi.org/10.1007/s13300-016-0167-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.